Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2626

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2626
---
 litigation or other
intellectual property related proceedings could adversely affect our ability to compete in the marketplace.

We
may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.

Because
our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth
of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.

100

Our
product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others.
We may develop products containing our drug substance and pre-existing biopharmaceutical compounds. We may be unable to acquire or in-license
any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as
necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable
terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party
intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property
rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be
feasible. Even if we are able to obtain a license or sublicense, it may be nonexclusive, thereby giving our competitors access to the
same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology.

Additionally,
we currently collaborate and intend to continue collaborating with academic institutions to facilitate and/or complement our preclinical
research and/or clinical development under written agreements with these institutions. In certain cases, these institutions may provide
us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless
of such options, if we are granted one, we may be unable to negotiate a license within the specified timeframe or under terms that are
acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking
our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to
maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial
condition could suffer.

The
licensing and acquisition of third-party intellectual property rights is a competitive